Medisca Inc. Resolves Investigation with DOJ
Medisca Inc. has successfully reached an agreement with the United States Department of Justice (DOJ). This settlement marks an important resolution of a civil investigation that had been ongoing for nine years. The DOJ's investigation was centered around allegations concerning the accuracy of Medisca's disclosure of average wholesale prices (AWPs) for specific pharmaceutical ingredients. These allegations pertain to the period from January 2012 to May 2015, particularly regarding how these prices affected reimbursements from the TRICARE program for pharmacies that acquired these ingredients at lower prices.
Shifting Practices in Pharmaceutical Pricing
The investigation brought to light practices that are now obsolete. Importantly, Medisca has not provided AWPs to pricing listing agencies for several years. Additionally, since 2016, the TRICARE program has ceased using AWPs to reimburse pharmacies for prescription claims. This change reflects a significant evolution in how pharmaceutical pricing and reimbursements are managed in the healthcare environment.
The Impact of the Settlement
It is imperative to note that the resolution of this investigation does not imply any admission of wrongdoing by Medisca Inc. The settlement allows the company to move forward without the burdens of business uncertainty or the potential costs associated with a formal complaint, legal proceedings, or prolonged litigation. For Medisca, this conclusion provides a clear path forward to concentrate on its core operations.
Future Growth and Personalized Wellness
With this chapter now closed, Medisca Inc. is excited to shift its focus toward strategic growth initiatives. The company is committed to its vision of empowering personalized wellness. By bridging the existing gaps in healthcare globally, Medisca aims to enhance the health and well-being of individuals. The company understands the importance of innovation in healthcare and aims to deliver personalized solutions that address the unique needs of patients around the world.
Frequently Asked Questions
What was the purpose of the DOJ investigation against Medisca?
The investigation aimed to assess allegations related to the accuracy of Medisca's disclosures of average wholesale prices for pharmaceutical ingredients and its impact on TRICARE reimbursements.
How long did the DOJ investigation last?
The investigation has been ongoing for nine years before reaching a settlement.
What does the settlement mean for Medisca?
The settlement allows Medisca to resolve the investigation without any admission of wrongdoing, enabling the company to refocus on its growth and wellness initiatives.
How have TRICARE's reimbursement practices changed?
TRICARE has not used average wholesale prices as the basis for reimbursement since 2016, marking a significant change in their pricing structures.
What is Medisca's future vision for healthcare?
Medisca aims to empower personalized wellness by bridging gaps in healthcare globally, focusing on innovative and individualized solutions for patients.
